A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

NCT04094662 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

393

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Peripheral Neuropathic Pain

Interventions

DRUG: Mirogabalin
DRUG: Placebo

Sponsor

Daiichi Sankyo Co., Ltd.